do glp 1 not work for some people 7 Reasons You Aren't Losing Weight on Weight Loss Drugs Weight loss drugs reduce some

Subsequent trials demonstrated cardiovascular benefits: in the SUSTAIN 6 trial, semaglutide reduced major adverse cardiovascular events by 26% in high-risk patients, a finding that led to FDA approval for cardiovascular risk reduction in January 2020

The initial consultation fee is $100, which goes toward your medication cost

Clinicians should systematically evaluate these potential causes when patients report persistent fatigue during GLP-1 therapy, as many are modifiable through dietary counseling, hydration strategies, or medication adjustment

Importantly for weight management, semaglutide also affects areas of the brain that control appetite, helping you feel fuller for longer and reducing hunger

Selection of reported studies: Studies reported in the text and above in the table were selected according to data relevancy and currency